Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics Launches $32.2M Stock Offering

NEW YORK (GenomeWeb) – NeoGenomics today said that it has priced an offering of 7 million shares of common stock at $4.60 per share.

The Ft. Myers, Fla.-based genetic testing services firm expects to raise gross proceeds of $32.2 million from the offering, which is expected to close on Aug. 20. Net proceeds are anticipated at around $30 million.

NeoGenomics said it will use the proceeds from the offering for working capital and general corporate purposes, which could include potential acquisitions and repayment of debt.

William Blair is the sole book-running manager on the offering, and Craig-Hallum Capital Group is co-lead manager. Stephens, Roth Capital Partners, Sidoti & Co., and Dawson James Securities are serving as co-managers on the offering.

The underwriters have a 30-day option to purchase up to an additional 1.05 million shares of common stock to cover any over-allotments.

NeoGenomics recently reported a 33 percent increase in second quarter revenues year over year and turned a profit in the quarter of $274,000, or $.01 per share. As of June 30 it held $5.0 million in cash and cash equivalents.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.